Article
Cardiac & Cardiovascular Systems
P. Christian Schulze, Juergen Bogoviku, Julian Westphal, Pawel Aftanski, Franz Haertel, Sissy Grund, Stephan von Haehling, Ulrike Schumacher, Sven Moebius-Winkler, Martin Busch
Summary: This study suggests that early addition of empagliflozin to standard diuretic therapy can increase urine output in patients with acute decompensated heart failure without affecting renal function.
Article
Cardiac & Cardiovascular Systems
Nirav Y. Raval, Ali Valika, Philip B. Adamson, Christopher Williams, Marie-Elena Brett, Maria Rosa Costanzo
Summary: Hemodynamic-guided heart failure management is an effective strategy to prevent hospitalization and preserve renal function across severities of comorbid renal insufficiency. This strategy involves remotely obtaining pulmonary artery pressures to guide treatment.
CIRCULATION-HEART FAILURE
(2023)
Review
Cardiac & Cardiovascular Systems
Arjun K. Pandey, Deepak L. Bhatt, Francesco Cosentino, Nikolaus Marx, Ori Rotstein, Bertram Pitt, Ambirash Pandey, Javed Butler, Subodh Verma
Summary: Despite current treatment options, patients with heart failure and chronic kidney disease (CKD) remain at high risk for adverse outcomes and disease progression. Non-steroidal mineralocorticoid receptor antagonists (MRAs) have emerged as a new dimension in the treatment of cardiorenal disease, offering unique pharmacological properties and benefits. These agents have anti-inflammatory, anti-remodelling, and anti-fibrotic effects in the heart, kidneys, and blood vessels. Although there are several non-steroidal MRAs in development, only esaxerenone and finerenone have been approved globally.
EUROPEAN HEART JOURNAL
(2022)
Review
Pharmacology & Pharmacy
Alexandre O. Gerard, Audrey Laurain, Antoine Sicard, Diane Merino, Atul Pathak, Milou-Daniel Drici, Guillaume Favre, Vincent L. M. Esnault
Summary: This article discusses the importance of diuretics in patients with diabetes mellitus, emphasizing the use of a combined diuretics strategy to improve renal and cardiac protection.
Article
Cardiac & Cardiovascular Systems
Shigeki Yokoyama, Teruhiko Imamura, Shigeyuki Yamashita, Toshio Doi, Kazuaki Fukahara, Naoki Yoshimura, Koichiro Kinugawa
Summary: This study investigated the changes in specific substances in urine and blood after cardiac surgery and found that the effect of tolvaptan on renal tubular activity was minimal within 6 hours postoperatively.
INTERNATIONAL HEART JOURNAL
(2021)
Article
Cardiac & Cardiovascular Systems
Wouter Ouwerkerk, Jasper Tromp, John G. F. Cleland, Christiane E. Angermann, Ulf Dahlstrom, Georg Ertl, Mahmoud Hassanein, Sergio Perrone, Mathieu Ghadanfar, Anja Schweizer, Achim Obergfell, Kenneth Dickstein, Gerasimos Filippatos, Sean P. Collins, Carolyn S. P. Lam
Summary: In patients with acute heart failure, delayed administration of intravenous diuretics was not significantly associated with in-hospital mortality, but was associated with increased 30-day mortality, especially in high-risk patients. This association was independent of left ventricular ejection fraction or geographic region.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Cardiac & Cardiovascular Systems
Himika Ohara, Akiomi Yoshihisa, Yuko Horikoshi, Shinji Ishibashi, Mitsuko Matsuda, Yukio Yamadera, Yukiko Sugawara, Yasuhiro Ichijo, Yu Hotsuki, Koichiro Watanabe, Yu Sato, Tomofumi Misaka, Takashi Kaneshiro, Masayoshi Oikawa, Atsushi Kobayashi, Yasuchika Takeishi
Summary: The renal venous stasis index (RVSI) assessed by renal Doppler ultrasonography is associated with parameters of cardiac function and right heart catheterization (RHC) in patients with heart failure (HF), and is also linked to adverse prognosis.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Urology & Nephrology
Kota Kakeshita, Tsutomu Koike, Teruhiko Imamura, Hayato Fujioka, Hidenori Yamazaki, Koichiro Kinugawa
Summary: This study investigated the role of urine cyclic adenosine monophosphate (AMP)/plasma arginine vasopressin (AVP) ratio in predicting the response of chronic kidney disease (CKD) patients with heart failure to tolvaptan. The results showed that the urine cyclic AMP/plasma AVP ratio is an important predictor of the response to tolvaptan.
CLINICAL AND EXPERIMENTAL NEPHROLOGY
(2023)
Review
Medicine, General & Internal
Monarch Shah, Alaa S. Awad, Emaad M. Abdel-Rahman
Summary: Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, shows promising therapeutic effects in heart failure and chronic kidney disease. Clinical trials demonstrate its efficacy in improving kidney and cardiovascular outcomes, particularly in patients with CKD and T2DM.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Gerasimos Filippatos, Stefan D. Anker, Rajiv Agarwal, Luis M. Ruilope, Peter Rossing, George L. Bakris, Christoph Tasto, Amer Joseph, Peter Kolkhof, Andrea Lage, Bertram Pitt
Summary: Finerenone reduces the incidence of new-onset HF and improves other HF outcomes in patients with chronic kidney disease and type 2 diabetes, regardless of a history of HF.
Article
Cardiac & Cardiovascular Systems
Satyam Sarma, James P. MacNamara, Bryce N. Balmain, Christopher M. Hearon, Denis J. Wakeham, Andrew R. Tomlinson, Linda S. Hynan, Tony G. Babb, Benjamin D. Levine
Summary: Exercise intolerance is a common symptom in patients with heart failure with preserved ejection fraction (HFpEF), which is believed to be caused by a marked rise in pulmonary capillary wedge pressure (PCWP). This study investigated the effect of nitroglycerin on PCWP and exercise capacity in patients with HFpEF. The results showed that nitroglycerin successfully reduced PCWP during exercise, but did not improve peak oxygen uptake. These findings suggest that reducing PCWP alone is not sufficient to enhance exercise capacity in patients with HFpEF.
Article
Cardiac & Cardiovascular Systems
Masami Nishino, Akihiro Tanaka, Shodai Kawanami, Hiroki Sugae, Kohei Ukita, Akito Kawamura, Hitoshi Nakamura, Yutaka Matsuhiro, Koji Yasumoto, Masaki Tsuda, Naotaka Okamoto, Yasuharu Matsunaga-Lee, Masamichi Yano, Yasuyuki Egami, Jun Tanouchi
Summary: The short-term effectiveness of tolvaptan for heart failure has been established, but its long-term effects are still controversial. This study found that the dose of tolvaptan and a history of heart failure admission were significantly associated with rehospitalizations within 1 year. Low-dose tolvaptan may be beneficial in reducing the risk of rehospitalizations.
INTERNATIONAL HEART JOURNAL
(2022)
Article
Cardiac & Cardiovascular Systems
Ali Vazir, Chris J. Kapelios, Elif Agaoglu, Marco Metra, Yury Lopatin, Petar Seferovic, Wilfred Mullens, Gerasimos Filippatos, Giuseppe Rosano, Andrew J. S. Coats, Ovidiu Chioncel
Summary: There is significant variability in the management of acute decompensated heart failure (ADHF) among physicians and between cardiologists and non-cardiologists. This includes differences in the use of diuretics, assessment of congestion, treatment goals, and response evaluation. Cardiologists tend to have different strategies and targets compared to non-cardiologists.
EUROPEAN JOURNAL OF HEART FAILURE
(2023)
Article
Urology & Nephrology
Patrick Rossignol, Bertram Pitt
Summary: Old-generation potassium binders have poor tolerability and lack randomized data to support their chronic use for managing hyperkalaemia. In contrast, two new potassium binders, patiromer and sodium zirconium cyclosilicate, have been shown to be safe and well tolerated for chronic management of hyperkalaemia, enabling RAASi optimization. Clinicians should now use these new potassium binders to treat hyperkalaemia.
CLINICAL KIDNEY JOURNAL
(2023)
Article
Medicine, General & Internal
Alberto Palazzuoli, Gaetano Ruocco, Paolo Severino, Luigi Gennari, Filippo Pirrotta, Andrea Stefanini, Francesco Tramonte, Mauro Feola, Massimo Mancone, Francesco Fedele
Summary: The study evaluated the effects of adding oral metolazone on diuretic response, clinical congestion, NTproBNP values, and renal function in patients with advanced heart failure. Patients who received metolazone in addition to traditional loop diuretic treatment showed better diuretic response and congestion score at discharge compared to those who only continued furosemide. The findings suggest that metolazone administration may be helpful in reducing the amount of loop diuretics and have positive implications for patients with advanced heart failure.
JOURNAL OF CLINICAL MEDICINE
(2021)
